{"title":"Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8<sup>+</sup> T cells through IL-9.","authors":"Ruixue Yang, Xuejiao Zeng, Xierenguli Alimu, Jianhua Qu","doi":"10.1007/s00262-025-04082-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study investigated the impact of innate lymphoid cell type 2 (ILC2s) on the function of regulatory T cells (Treg) and CD8<sup>+</sup> T cells in chronic lymphocytic leukemia (CLL) through IL-9.</p><p><strong>Methods: </strong>Peripheral blood samples were collected from CLL patients (n = 52) and healthy controls (n = 30). ILC2 proportions and IL-9 levels were assessed using flow cytometry and ELISA. Immunofluorescence staining was performed to stain GATA3, CRTH2, and IL-9 in cervical lymph nodes from CLL patients (n = 10) and control subjects with reactive lymphadenitis (n = 10). Correlation analysis between ILC2s and IL-9 was conducted using the Spearman test. ILC2s were sorted and cultured from CLL patients, followed by co-culture experiments with PBMCs of healthy controls and MEC-1 cells, with or without anti-IL-9 antibody intervention. Flow cytometry was used to measure the proportions of ILC2s, Treg cells, PD-1<sup>+</sup>/TIGIT<sup>+</sup>/CTLA-4<sup>+</sup> Treg subsets, and granzyme B<sup>+</sup>/perforin<sup>+</sup> CD8<sup>+</sup> T cells, along with MEC-1 cell apoptosis.</p><p><strong>Results: </strong>The proportions of ILC2s and Treg, along with serum IL-9 levels, were significantly elevated in CLL patients (P < 0.05). Peripheral blood ILC2s were positively correlated with IL-9 (r = 0.609, P < 0.001). The average fluorescence intensity of GATA3, CRTH2, and IL-9 in the cervical lymph nodes of CLL patients increased significantly (P < 0.001), and IL-9 showed colocalization with GATA3 and CRTH2. In vitro, IL-9 levels in the supernatant of sorted ILC2s from CLL patients increased. Treatment with anti-IL-9 antibody significantly reduced the PD-1<sup>+</sup> Treg and TIGIT<sup>+</sup> Treg cells while increasing granzyme B<sup>+</sup> CD8<sup>+</sup> T cells (P < 0.05). However, there was no significant effect on Treg, CTLA-4<sup>+</sup> Treg, and perforin<sup>+</sup> CD8<sup>+</sup> T cells (P > 0.05). Additionally, anti-IL-9 antibody significantly increased early apoptosis (P < 0.05).</p><p><strong>Conclusion: </strong>ILC2s affect CD8<sup>+</sup> T cells and Treg cells through IL-9, weakening the anti-tumor effects of CD8<sup>+</sup> T cells and enhancing the immunosuppressive effects of Treg cells, thereby contributing to CLL pathogenesis.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":"74 7","pages":"228"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125456/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer immunology, immunotherapy : CII","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00262-025-04082-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study investigated the impact of innate lymphoid cell type 2 (ILC2s) on the function of regulatory T cells (Treg) and CD8+ T cells in chronic lymphocytic leukemia (CLL) through IL-9.
Methods: Peripheral blood samples were collected from CLL patients (n = 52) and healthy controls (n = 30). ILC2 proportions and IL-9 levels were assessed using flow cytometry and ELISA. Immunofluorescence staining was performed to stain GATA3, CRTH2, and IL-9 in cervical lymph nodes from CLL patients (n = 10) and control subjects with reactive lymphadenitis (n = 10). Correlation analysis between ILC2s and IL-9 was conducted using the Spearman test. ILC2s were sorted and cultured from CLL patients, followed by co-culture experiments with PBMCs of healthy controls and MEC-1 cells, with or without anti-IL-9 antibody intervention. Flow cytometry was used to measure the proportions of ILC2s, Treg cells, PD-1+/TIGIT+/CTLA-4+ Treg subsets, and granzyme B+/perforin+ CD8+ T cells, along with MEC-1 cell apoptosis.
Results: The proportions of ILC2s and Treg, along with serum IL-9 levels, were significantly elevated in CLL patients (P < 0.05). Peripheral blood ILC2s were positively correlated with IL-9 (r = 0.609, P < 0.001). The average fluorescence intensity of GATA3, CRTH2, and IL-9 in the cervical lymph nodes of CLL patients increased significantly (P < 0.001), and IL-9 showed colocalization with GATA3 and CRTH2. In vitro, IL-9 levels in the supernatant of sorted ILC2s from CLL patients increased. Treatment with anti-IL-9 antibody significantly reduced the PD-1+ Treg and TIGIT+ Treg cells while increasing granzyme B+ CD8+ T cells (P < 0.05). However, there was no significant effect on Treg, CTLA-4+ Treg, and perforin+ CD8+ T cells (P > 0.05). Additionally, anti-IL-9 antibody significantly increased early apoptosis (P < 0.05).
Conclusion: ILC2s affect CD8+ T cells and Treg cells through IL-9, weakening the anti-tumor effects of CD8+ T cells and enhancing the immunosuppressive effects of Treg cells, thereby contributing to CLL pathogenesis.